Popular terms

[SEARCH]

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      
           
This page is updated frequently with new Antibodies-related patent applications. Subscribe to the Antibodies RSS feed to automatically get the update: related Antibodies RSS feeds. RSS updates for this page: Antibodies RSS RSS



Date/App# patent app List of recent Antibodies-related patents
08/20/15
20150233944 
 Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia patent thumbnailDiagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
Described herein are methods and systems for the detection of anti-vinculin antibodies, for determining a presence or likely presence of a gastrointestinal motility disorder, bladder motility disorder, or fibromyalgia. Further provided are methods of selecting and/or administering a therapy based on the presence or absence of anti-vinculin antibodies..
Cedars-sinai Medical Center


08/20/15
20150233943 
 Blid; a novel protein domain for interaction with the bcl-2 family of proteins patent thumbnailBlid; a novel protein domain for interaction with the bcl-2 family of proteins
In this invention, a novel protein interaction domain is provided along with several of its variants. This domain is involved in protein-protein interactions with the bcl-2 family of proteins.

08/20/15
20150233941 
 Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection patent thumbnailSubstances, vaccines and methods for diagnosing and reducing incidences of transplant rejection
Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. The method for screening an allograft recipient (including pregnant women) for chronic allograft rejection comprises the steps of measuring an amount of a natural antibody within a biological sample and comparing the amount of the first natural antibody with the amount of the first natural antibody present within a control sample; wherein a decrease in the amount of the first natural antibody as compared to those levels seen in the control indicates a diagnosis of being at-risk for or experiencing chronic allograft rejection.
3dt Holdings, Llc


08/20/15
20150233924 
 Methods for identifying hiv neutralizing antibodies patent thumbnailMethods for identifying hiv neutralizing antibodies
The present invention relates to an in vitro method for determining hiv neutralizing antibodies in a sample. It further relates to a fusion protein to be used in said method and a nucleic acid encoding said fusion protein..
FundaciÓ Privada Institut De Recerca De La Sida - Caixa


08/20/15
20150233922 
 Method for measuring hemagglutinin from influenza virus patent thumbnailMethod for measuring hemagglutinin from influenza virus
Disclosed is a novel method for measuring haemagglutinin of an influenza virus, which can construct an assay system in a shorter period of time than a sandwich immunoassay method using two kinds of anti-haemagglutinin antibodies. The method for measuring haemagglutinin of an influenza virus is achieved by a sandwich immunoassay method comprising sandwiching the haemagglutinin between a lectin which binds to the haemagglutinin but does not bind to an antibody, and an anti-haemagglutinin antibody which undergoes antigen-antibody reaction with the haemagglutinin..
Denka Seiken Co., Ltd.


08/20/15
20150233918 
 Methods and systems for rapid detection of microorganisms using free antibodies patent thumbnailMethods and systems for rapid detection of microorganisms using free antibodies
Disclosed herein are methods and systems for detection of a microorganism of interest using an amplification assay. The methods and systems utilize the specificity of binding agents, such as antibodies, to rapidly detect low levels of a specific microorganism present in a sample.
Laboratory Corporation Of America Holdings


08/20/15
20150233914 
 Compositions and methods for detecting autoantibodies patent thumbnailCompositions and methods for detecting autoantibodies
The invention provides compositions and methods for detecting thyroid hormone blocking immunoglobulin (tbi). The invention's methods are sensitive and specific for tbi, and may be used for the dual detection of both tbi and tsi.
Quidel Corporation


08/20/15
20150232577 
 Anti-biotin antibodies and methods of use patent thumbnailAnti-biotin antibodies and methods of use
The invention provides anti-biotin antibodies and methods of using the same.. .
Hoffmann-la Roche Inc.


08/20/15
20150232574 
 Predictive marker for topoisomerase i inhibitors patent thumbnailPredictive marker for topoisomerase i inhibitors
The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase i (topo i) inhibitors in the treatment of cancers.
Boston Medical Center Corporation


08/20/15
20150232573 
 Anti-egfr/anti-her2 bispecific antibodies with anti-egfr darpins patent thumbnailAnti-egfr/anti-her2 bispecific antibodies with anti-egfr darpins
An anti-egfr/anti-her2 bispecific antibody including an anti-egfr darpin and an anti-her2 antibody, a pharmaceutical composition including the bispecific antibody, a method of preparing the bispecific antibody, and a method of reducing a side effect and/or enhancing efficacy of an anti-her2 antibody using an anti-egfr darpin.. .
Samsung Electronics Co., Ltd.


08/20/15
20150232571 

Anti-cd38 human antibodies and uses therefor


The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for cd38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma.
Morphosys Ag


08/20/15
20150232570 

Methods of treating hematological malignancies with notch1 antibodies


Notch1-binding antibodies and methods of using the antibodies for treating hematologic cancers are disclosed. Methods of using antibodies that bind to a non-ligand binding membrane proximal region of the extracellular domain of human notch1 and methods of treating chronic lymphocytic leukemia (cll), hairy cell leukemia, chronic myelogenous leukemia (cml), nonhodgkin lymphoma, diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), or cutaneous t-cell lymphoma (ctcl) in a subject, comprising administering a therapeutically effective amount of a notch1-binding antibody to the subject are also disclosed.
Oncomed Pharmaceuticals, Inc.


08/20/15
20150232569 

Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis


The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ror1 antibodies or antigen binding fragments, ror1 binding peptides and ror1 vaccines.. .
The Regents Of The University Of California


08/20/15
20150232568 

Anti-jagged antibodies and methods of use


The disclosure provides anti-jagged antibodies and methods of using the same.. .
Genentech, Inc.


08/20/15
20150232563 

Novel mutated humanized 12g4 antibodies and the fragments thereof against the human anti-mullerian hormone receptor type ii


Novel mutated humanized 12g4 antibodies, and fragments thereof, directed against the anti-müllerian hormone type ii receptor.. .
I.n.s.e.r.m. (institut National De La Sante Et De La Recherche Medicale)


08/20/15
20150232560 

Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof


Herein is reported a method for determining a combination of antigen binding sites comprising the steps of (i) determining the binding specificity and/or affinity and/or effector function and/or in vivo half-life of a multitude of bispecific antibodies prepared by combining each member of a first multitude of antibody fab fragments or scfv antibody fragments with each member of a second multitude of antibody fab fragments or scfv antibody fragments, and a linker comprising at one of its termini the second member of the first binding pair and at the respective other terminus the second member of the second binding pair, whereby the first multitude specifically binds to a first cell surface molecule and the second multitude specifically binds to a second cell surface molecule, and (ii) choosing the bispecific antibody with suitable binding specificity and/or affinity and/or effector function and/or in vivo half-life and thereby determining a combination of antigen binding sites.. .
Hoffmann-la Roche Inc.


08/20/15
20150232559 

Anti-alpha2 integrin antibodies and their uses


The invention relates to antibodies directed to α2β1 integrin and their uses, including humanized anti-alpha 2 (α2) integrin antibodies and methods of treatment with anti-α2 integrin antibodies. More specifically the present invention relates to humanized anti-α2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human igg1 heavy chain constant region which exhibit altered effector function..
Sanofi


08/20/15
20150232557 

Cd3 binding polypeptides


The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with cd3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scfvs, fabs, di-scfvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments.
Emergent Product Development Seattle Llc


08/20/15
20150232556 

Kir3dl2 binding agents


The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. Monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind kir3dl2.
Innate Pharma


08/20/15
20150232555 

Antibodies to human programmed death receptor pd-1


antibodies which block binding of hpd-1 to hpd-l1 or hpd-l2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the pd-1 pathway is also disclosed..
Merck Sharp & Dohme B.v.


08/20/15
20150232554 

Frizzled-binding agents and uses thereof


Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified.
Oncomed Pharmaceuticals, Inc.


08/20/15
20150232553 

Function modifying nav1.7 antibodies


A nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.. .
Ucb Biopharma Sprl


08/20/15
20150232552 

Antibodies that bind il-23


The present invention provides an antibody that binds to the p19 subunit of human il-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome.
Eli Lilly And Company


08/20/15
20150232551 

Antibodies directed to il-17a/f heterologous polypeptides and therapeutic uses of thereof


The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17f designated herein as interleukin 17a/f (il-17a/f). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Genentech, Inc.


08/20/15
20150232549 

Anti-vegf antibodies


Anti-vegf antibodies and variants thereof, including those having high affinity for binding to vegf, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-vegf antibodies with desired binding and other biological activities.
Genentech, Inc.


08/20/15
20150232548 

Combination therapy with an anti-ang2 antibody and a cd40 agonist


The present invention relates to the combination therapy of an antibodies that binds to human angiopoietin 2 (ang-2) with a cd40 agonist.. .
Hoffmann-la Roche Inc.


08/20/15
20150232546 

Anti-pdgf-c antibodies


The invention relates to antibodies binding to the pdgf-c antigen and capable of inhibiting binding of pdgf-c to the pdgfrα receptor and of inhibiting pdgfrα activation by pdgf-c. Applications of such antibodies are also disclosed.
Thrombogenics Nv


08/20/15
20150232545 

Human antibodies to human delta like ligand 4


The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hdll4) and blocks hdll4 binding to a notch receptor. The anti-hdll4 antibody or fragment thereof of the present invention have a high affinity with the kd of 500 pm or less, as measured by surface plasmon resonance..
Regeneron Pharmaceuticals, Inc.


08/20/15
20150232544 

Methods of treating a tauopathy


The present disclosure provides methods of treating a tauopathy, involving administering an anti-tau antibody. The present disclosure also provides anti-tau antibodies, and formulations comprising same, for use in the methods..
Ipierian, Inc.


08/20/15
20150232543 

Acceptor framework for cdr grafting


The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications..
Esbatech - A Novartis Company Llc


08/20/15
20150232542 

Human anti-alpha-synuclein antibodies


Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed.
University Of Zurich


08/20/15
20150232539 

Methods and compositions for detecting, imaging, and treating small cell lung cancer utilizing post-translationally modified residues and higher molecular weight antigenic complexes in proteins


The present invention discloses ectopically expressed isoaspartylated proteins and antigenic peptide fragments thereof as potential biomarkers for cancer such as small cell lung cancer. Also disclosed are antigen recognition agents capable of specifically recognizing and binding to isoaspartylated proteins and/or antigenic peptide fragments thereof.
University Of Southern California


08/20/15
20150232538 

Monoclonal antibodies for ebola and marburg viruses


Described herein are a number of ebola monoclonal antibodies.. .
Her Majesty The Queen In The Right Of Canada As Represented By The Minister Of Health


08/20/15
20150232537 

Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof


The disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to hepatitis b viruses, and have a broad neutralizing activity against such hepatitis b viruses. The disclosure further provides nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules.
Crucell Holland B.v.


08/20/15
20150232518 

Treatment of microbial infections


The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal mscramm or mscramm-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy..
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe


08/20/15
20150231242 

Combination of cd37 antibodies with bendamustine


The present invention relates to immunotherapies that are based on depletion of cd37-positive cells such as b-cells. The present invention provides methods for reduction of cd37-positive cells such as b-cells in an individual/patient using a combination of cd37 antibody/antibodies and bendamustine.
Boehringer Ingelheim International Gmbh


08/20/15
20150231241 

Combination therapy for inducing immune response to disease


The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.


08/20/15
20150231240 

Anti-c16orf54 antibodies and methods of use thereof


The invention provides antibodies that bind c16orf54, including antibody-drug conjugates comprising the antibodies, and methods of use of the antibodies and the antibody-drug conjugates, including for the diagnosis and treatment of cancers.. .
Igenica Biotherapeutics, Inc.


08/20/15
20150231237 

Methods and products for treating proliferative diseases


Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline, exemplified by chloroquine, with a glycolytic inhibitor, exemplified by 2-deoxy-d-glucose and anti-vegf antibodies.
The Regents Of The University Of Colorado, A Body Corporate


08/20/15
20150231234 

Use of anti-cd1 antibodies for the modulation of immune responses


The invention provides methods for the administration of an anti-cd1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.. .
Beth Israel Deaconess Medical Center, Inc.


08/20/15
20150231233 

Method and system to remove soluble tnfr1, tnfr2, and il2 in patients


A method, and system, to induce remission in diseases characterized by excess production of stnr and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to stnfr1, stnfr2 and sil2r immobilized in a column containing a material such as sepharose™.

08/20/15
20150231220 

Epitopes of epidermal growth factor receptor surface antigen and use thereof


The present invention relates to epitopes of the epidermal growth factor receptor (egfr) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (egf).
Green Cross Corporation


08/20/15
20150231219 

Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies


Provided are methods for the administration of therapeutic bispecific anti-igf-1r and anti-erbb3 antibodies, either alone or in combination with other anti-cancer therapeutics.. .
Merrimack Pharmaceuticals, Inc.


08/13/15
20150226758 

Assays for detecting the presence or amount of an anti-drug antibody


Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum..
Genzyme Corporation


08/13/15
20150226742 

Novel the selection of specific affinity binders by homogeneous noncompetitive assay


The invention generally relates to the field of immunochemistry including antibody therapy, diagnostics, and basic research and specifically relates to the area of selecting affinity molecules such as natural antibodies, including artificial antibodies, antibody mimics, and aptamers. The invention relates particularly to a method of selecting affinity molecules using a homogeneous noncompetitive assay in a high throughput process..
Dynamic Affinity Reagents, Llc


08/13/15
20150226734 

Instant osteoarthritis test paper


An instant osteoarthritis test paper is used to detect a urine sample and comprises a substrate, a test result layer arranged on the substrate, a water absorption layer connecting with the substrate and partially covering the test result layer, an antibody release layer connecting with the substrate and partially covering the test result layer, and a sample reception layer connecting with the substrate and partially covering the antibody release layer. The test result layer includes a result indication zone and a control zone.

08/13/15
20150225685 

Biomanufacturing suite and methods for large-scale production of cells, viruses, and biomolecules


The present invention provides a production module for large-scale production of cells and/or cell-derived products such as antibodies or virus; a production suite comprising a plurality of functionally connected production modules of the invention; and a method for large-scale production of cells and/or cell-derived products using the production modules and/or production suites of the invention.. .
Biovest International, Inc.


08/13/15
20150225482 

Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics


antibodies of interest comprising a heavy chain signal peptide and/or a light chain signal peptide or combination thereof and compositions are described. The method of determining the signal peptide including creating data set of antibodies signal peptides, clustering, selecting and creating recombinant antibodies for enhanced expression and secretion are described..
Agency For Science, Technology And Research


08/13/15
20150225478 

Immunogenic and prophylactic compositions, methods of making same, and methods for treating and preventing tnf-mediated disease


An immunogenic composition comprises a peptide that induces in vivo tnf monomer-specific antibodies that bind an epitope of dissociated monomers of human tnf, the epitope being located wholly or partially within a tnf monomer-monomer interface region. Antibodies induced in vivo by this composition disrupt assembly or prevent re-assembly of the tnf monomers into bioactive trimeric human stnf.
Thymon, Llc


08/13/15
20150225477 

Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease


An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf.
Thymon, Llc


08/13/15
20150225473 

Methods for purification of antibodies using aliphatic alcohols


This disclosure relates to methods for isolating antibodies from cell-free culture supernatant.. .

08/13/15
20150225456 

Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies


The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer..
The Board Of Regents Of The University Of Oklahoma


08/13/15
20150224192 

Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments


The present invention concerns methods and compositions for treatment of hiv infection in a subject. The compositions may comprise a targeting molecule against an hiv antigen, such as an anti-hiv antibody or antibody fragment.
Immunomedics, Inc.


08/06/15
20150219671 

Diagnostic kit for igfbp-4 proteolytic fragments in a patient sample


The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting igfbp-4 (insulin-like growth factor binding protein-4) fragments in a patient sample. antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of igfbp-4 are also disclosed..
Hytest Ltd.


08/06/15
20150219667 

Pre-transplant igg reactivity to apoptotic cells correlates with late kidney allograft loss


It has been discovered that significantly elevated levels of anti-apoptotic cell igg is an important contributor to and predictor of late graft rejection. Kaplan-meier survival analysis revealed that patients with high pre-transplant igg and post-transplant reactivity to apoptotic cells had a significantly increased rate of late graft loss that was apparent after approximately 1 year post-transplant.
The Trustees Of Columbia University In The City Of New York


08/06/15
20150219648 

Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies


Disclosed is a cell wall c-polysaccharide antigen of streptococcus pneumoniae which contains not more than 10% by weight of protein, and preferably less which has been purified with 0.1n na oh prior to deproteinizing. Also disclosed are polyvalent antibodies raised against streptococcus pneumoniae which have been affinity purified by passing them over a chromatographic affinity matrix to which is coupled the purified and at least partially deproteinized antigen to render them antigen-specific..
Alere Scarborough, Inc.


08/06/15
20150219646 

Compositions and methods for the detection of bacterial infections associated with lyme disease


The invention is directed to methods of assaying biological samples for the presence of antibodies or antigens indicative of infection by a bacterium of the borrelia burgdorferi sensu lato complex. Also included in the invention are devices that can be used in carrying out these methods.
The General Hositpal Corporaion


08/06/15
20150219629 

Sperm-specific cation channel, and uses therefor


Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (catsper1) are disclosed. The catsper1 protein is shown to be specifically expressed in sperm and to be necessary for sperm motility.
Children's Medical Center Corporation


08/06/15
20150219626 

Sperm-specific cation channel, catsper3, and uses therefor


Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (catsper3) are disclosed. The catsper3 protein is shown to be specifically expressed in sperm.
Children's Medical Center Corporation


08/06/15
20150219579 

Method for detecting autoantibodies


A method for the detection of autoantibodies comprises detecting autoantibodies in a sample from an individual using label free electrochemical impedance spectroscopy. In one aspect, the method is a method for the diagnosis or monitoring of parkinson's disease comprising detecting α-synuclein autoantibodies in a sample from an individual using electrochemical impedance spectroscopy.
Isis Innovation Limited


08/06/15
20150218583 

Axmi-234 and axmi-235 delta-endotoxin genes and methods for their use


Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
Athenix Corp.


08/06/15
20150218551 

Enhanced rapid immunogen selection hiv gp120 variants


The invention relates to an enhanced method for rapid immunogen selection (ris) based on the binding a library of recombinant viruses containing randomized variants of a surface polypeptide displayed to said neutralizing antibodies. The invention relates as well to the use of the immunogens isolated according to the ris method of the invention in medicine for the treatment of diseases caused by a virus and in diagnosis for the identification of neutralizing antibodies in a patient..
FundaciÓ Privada Institut De Recerca De La Sida - Caixa


08/06/15
20150218290 

Usp2a peptides and antibodies


The invention relates to novel usp2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment..
Nuclea Biotechnologies, Inc.


08/06/15
20150218289 

Anti-transglutaminase 2 antibodies


The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (tg2). Novel epitopes within the tg2 core are provided.
Medical Research Council Technology


08/06/15
20150218287 

Tumor selective antibodies specific to oncofetal antigen/immature laminin receptor protein


Disclosed are high affinity antibodies or antigen-binding fragments thereof, which bind an epitope that lies within the c-terminal region of oncofetal antigen (ofa)/immature laminin receptor protein (ilrp), and which do not substantially cross-react with mature ofa/lrp. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy.
South Alabama Medical Science Foundation


08/06/15
20150218284 

Cd27l antigen binding proteins


The present invention relates to cd27l antigen binding proteins, such an antibodies, polynucleotides encoding said cd27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with cd27l expression.. .
Amgen Inc.


08/06/15
20150218283 

Antibodies to non-functional oligomeric p2x7 receptors


The invention relates to purinergic receptors, to antibodies and related fragments thereof for binding to said receptors, to production of said antibodies and fragments and to sue of said antibodies and fragments for cancer detection and therapy. In particular the antibodies described bind specifically to non-functional p2x& receptors expressed by live cells..
Biosceptre International Limited


08/06/15
20150218281 

Single variable domain antibodies against ox40l, constructs and therapeutic use


The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. Asthma, allergic asthma, chronic colitis, crohn's disease, inflammatory bowel disease, and/or arthrosclerosis..

08/06/15
20150218276 

Antibodies and methods of use


The presently disclosed subject matter provides antibodies that bind klb and fgfr1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on fgfr1 and binds to an epitope present on klb..
Genentech, Inc.


08/06/15
20150218273 

Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications


The present invention relates to antibodies against oncofetal antigen/immature laminin receptor protein (ofa/ilrp) that can be used singly or in conjunction to detect or treat ofa/ilrp-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring ofa/ilrp in different biofluids; and (ii) using ofa/ilrp with an antibody directed against the monomeric form and its associated diseases..
Benovus Bio, Inc.


08/06/15
20150218270 

Humanized anti-il 10 antibodies for the treatment of systemic lupus erythematosus (sle)


Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (il-10), wherein said antibody or fragment thereof: (i) binds to the same region of il-10 as the il-10 receptor α (il-i10ra) and is not capable of binding il-10 when the il-10 is bound to the il-10 receptor; and (ii) binds to il-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof..
Biotest Ag


08/06/15
20150218267 

Novel anti-baff antibodies


The present invention relates to anti-baff antibody molecules, including novel humanized anti-baff antibodies, therapeutic and diagnostic methods and compositions for using the same.. .
Boehringer Ingelheim International Gmbh


08/06/15
20150218266 

Inhibition of th17 cells migration to inflamed tissues using antibodies directed against mcam


Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting t cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (mcam) are disclosed.. .
Val-chum, Limited Partnership


08/06/15
20150218264 

Methods for the humanization of antibodies and humanized antibodies thereby obtained


Method for the humanization of the vh and vl variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-ngf and anti-trka humanized animal antibodies.. .
Abbvie Research B.v.


08/06/15
20150218262 

Method for in-vivo binding of chromatin fragments


A process for substantially reducing levels of circulating chromatin fragments (ccfs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginates, chitosan and pullulan to form complexed antibodysubstrate nano-particulates (cnp) to bind and/or inactivate ccfs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer.
Tata Memorial Centre


08/06/15
20150218261 

Amyloid-beta binding proteins


The present invention relates to amyloid-beta (aβ) binding proteins. antibodies of the invention have high affinity to aβ(20-42) globulomer or any aβ form that comprises the globulomer epitope.
Abbvie Inc.


08/06/15
20150218257 

Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity


The invention provides a method for obtaining a broadly neutralizing antibody (bnab), including screening memory b cell cultures from a donor pbmc sample for neutralization activity against a plurality of hiv-1 species, cloning a memory b cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory b cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the env proteins in native or monomeric form, as well as to inhibit infection of hiv-1 species from a plurality of clades.
The Scripps Research Institute


08/06/15
20150218255 

Cross-reactive antibodies against dengue virus and uses thereof


The invention relates to a human anti-dengue virus antibody (an anti-denv antibody) that binds to a denv envelope protein and is cross-reactive with denv serotype 1, denv serotype 2, denv serotype 3, and denv serotype 4. The disclosure provides an anti-denv antibody that cross-reacts with and neutralizes all four denv serotypes.
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services


08/06/15
20150218244 

Interleukin-10 fusion proteins and uses thereof


The present invention generally relates to fusion proteins of antibodies and interleukin-10 (il-10). More particularly, the invention concerns fusion proteins of antibodies and mutant il-10 that exhibit improved properties for use as therapeutic agents, e.g.
Hoffmann-la Roche Inc.


08/06/15
20150218232 

Artificial forisome body with seo-f fusion proteins, plant or yeast cells comprising vectors which code for these proteins, as well as vectors which code for seo-f fusion proteins


The artificial forisome body of the invention is useful for protein-chemistry purposes, particularly for providing immobilized enzymes, antibodies, antigens, as well as such proteins or peptides that can be immobilized on a substrate due to their affinity reaction with a substrate-bound biological or biochemically produced material.. .

08/06/15
20150218217 

Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof


The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (upa), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.. .
Cytomx Therapeutics, Inc.


08/06/15
20150218209 

Preparation and/or purification of oligonucleotide conjugates


Methods, systems and/or kits for the preparation, purification and isolation of oligonucleotide conjugates, comprising conjugation of modified antibodies or proteins with at least one modified oligonucleotide at greater than 80% efficiency to form oligonucleotide conjugates and isolating the oligonucleotide conjugates from the conjugation solution by binding the conjugates to an immobilized binder, wherein the binder may be a metal ion or an antibody.. .
Solulink, Inc.


08/06/15
20150216998 

Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents


Disclosed herein are compositions comprising lipid based particles and anti-endo180 antibodies and to methods of using the same for targeted delivery of therapeutic agents to cancer and fibrotic cells useful for treating cell proliferative diseases or disorders including fibrosis, cancer and to attenuate tumor progression.. .
Qbi Enterprises Ltd.


08/06/15
20150216997 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


08/06/15
20150216960 

Immunogenic compositions for the prevention and treatment of meningococcal disease


The present invention relates to neisseria orf2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by neisseria meningitidis serogroup b.. .
Wyeth Holdings Llc


08/06/15
20150216958 

Cancer peptide vaccine


A composition for treating cancer, comprising 6 to 13 peptides derived from tumor antigens, wherein the composition is used in the manner that antibodies to the respective peptides in the peripheral blood of a patient are measured and peptides to which antibodies are positive are selected and administered to the patient, and a peptide selection method.. .
Green Peptide Co., Ltd.




Popular terms: [SEARCH]

Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4713

4788

1 - 1 - 103